Photodynamic therapy: Principles and therapeutic indications;Principes et applications thérapeutiques de la photothérapie dynamique

Annales Pharmaceutiques Francaises

Volumn 67, Issue 1, 2009, Pages 32-40

  Ficheux, H ^a  

^a CIT   (France)

Author keywords

Lasers; Oncology; Photodynamic therapy; Photosensitizers; Porphyrins

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; BACTERIOCHLOROPHYLL; LUTETIUM TEXAPHYRIN; PADELIPORFIN; PALLADIUM BACTERIOPHEOPHORBIDE; PHOTOFRIN; PHOTOSENSITIZING AGENT; PORPHYRIN; STAKEL; TEMOPORFIN; UNCLASSIFIED DRUG; VERTEPORFIN; WST 11;

BLEACHING; DIGESTIVE SYSTEM CANCER; DRUG MONITORING; DRUG STRUCTURE; HALF LIFE TIME; HUMAN; LIGHT ABSORPTION; LOW LEVEL LASER THERAPY; LUNG CANCER; PANCREAS CANCER; PHOTODYNAMIC THERAPY; RESPIRATORY TRACT CANCER; RETINA MACULA AGE RELATED DEGENERATION; SHORT SURVEY; TISSUE DISTRIBUTION; URINARY TRACT CANCER; CHEMICAL STRUCTURE; CHEMISTRY; FEMALE; FIBER OPTICS; INSTRUMENTATION; LASER; MALE; METHODOLOGY; NEOPLASM; PHOTOCHEMISTRY; PHOTOCHEMOTHERAPY; RADIATION EXPOSURE; RETINA MACULA DEGENERATION; REVIEW; SOLUBILITY;

BACTERIOCHLOROPHYLLS; FEMALE; FIBER OPTIC TECHNOLOGY; HALF-LIFE; HUMANS; LASERS; MACULAR DEGENERATION; MALE; MOLECULAR STRUCTURE; NEOPLASMS; PHOTOCHEMICAL PROCESSES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 60849116968     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2008.10.013     Document Type: Short Survey

References (35)

1. Raab O. Uber die Wirkung fluoreszierenden Stoffen. Infusoria Z Biol 39 (1900) 524
2. Tappeiner H.V., and Jesionek A. Therapeutische Versuchi mit fluoreszierender Stoff. Muchen Med Wehnschr 1 (1903) 2042-2044
3. Blum H.F. Photodynamic action and diseases caused by light. (1941), Reinhold, New York Reprinted, New York Hafner 1964
4. Dougherty T.J., Kaufman J.E., and Goldfarb A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 38 (1978) 2628-2635
5. Zilberstein J., Schreiber S., Bloemers M.C.W.M., Bendel P., Neeman M., Schechtman E., et al. Antivascular treatment of solid melanoma tumors with bacteriochlorophyll-serine-based photodynamic therapy. Photochem Photobiol 73 (2001) 257-266
6. Wandel C., Kin R.B., and Stein C.M. "Inactive" excipients such as Cremophor can affet in vivo drug disposition. Clin Pharmacol Ther 73 (2003) 394-396
7. Potter W.R., Mang T.S., and Dougherty T.J. The theory of photodynamic therapy dosimetry: consequences of photodestruction of sensitizer. Photochem Photobiol 46 (1987) 97-101
8. Brancaleon L., and Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers Med Sci 17 (2002) 173-186
9. Stepinac T., Grosjean P., Woodtli A., Monnier P., Van Den Bergh H., and Wagnières G. Optimization of the diameter of a radial irradiation device for photodynamic therapy in the esophagus. Endoscopy 34 (2002) 411-415
10. Van Den Bergh H. On the evolution of some endoscopic light delivery systems for photodynamic therapy. Endoscopy 30 (1998) 392-407
11. Kessel D, Nseyo U, Schulz V, Sykes E. Pharmacokinetics of photofrin II distribution in man, in optical methods for tumor treatment and early diagnosis: mechanisms and techniques. Doughert TJ ed., 1991. SPIE:180-187.
12. Peng Q., Berg K., Moan J., Kongshaug M., and Mesland J.M. 5-aminolevulic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol 65 (1997) 235-251
13. Pariser D.M., Lowe N.J., Stewart D.M., Jarratt M.T., Lucky A.W., Pariser R.J., et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multi-center trial. J Am Acad Dermatol 48 (2003) 227-232
14. Van Den Bergh H., Ballini J.P., and Sickenberg M. Photodynamic therapy for subfoveal choroidal neovascularisation in various diseases among which age-related macular degeneration: an update. Med Laser Appl 18 (2003) 65-78
15. Trachtenberg J., Bogaards A., Gertner M., Weersink R.A., Yue C., Scherz A., et al. Vascular-targeted photodynamic therapy (VTP) with Tookad for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urology 178 (2007) 1974-1979
16. Berdugo M., Bejjani R.A., Valamanesh F., Savoldelli M., Jeanny J.-C., Blanc D., et al. Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes. Invest Ophtalmo Visual Sci 49 (2008) 1633-1644
17. Kessel D. Effects of photoactivated porphyrins at the cell surface of leukemia L1210 cells. Biochemistry 16 (1977) 3443-3449
18. Bugelski P.J., Porter C.W., and Dougherty T.J. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res 41 (1981) 4606-4612
19. Fabre M.A., Fuseau E., and Ficheux H. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collectd after single IV administration in healthy subjects and population PK modelling. J Pharm Sci 96 (2007) 3444-3456
20. Soubrane G., and Bressler N.M. Treatment of subfoveal choroidal neovasculatisation in age reated macular degeneration: focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol 85 (2001) 483-495
21. Prognon P., Kasselouri A., Desroches M., Blais J., and Maillard P. Tétrapyrroles anticancéreux photosensibilisants : ou comment la photophysique devient mécanisme d'action ?. Ann Pharm Fr 66 (2008) 71-76
22. Rodgers M.A.J., and Snowden P.T. Lifetime of O2 (1Δg) in liquid water as determined by time resolved infrared luminescence measurements. J Am Chem Soc 104 (1982) 5541-5543
23. Fu N.-W., Yeh S.-Y., Chang C., Zhao X.-H., and Chang L.-S. Photosensitization of mitochondrial adenosine-triphosphatase and adenylate kinase by hematoporphyrin derivative in vitro. In: Kesell D. (Ed). In methods in porphyrin photosensitization (1985), Plenum Press, New York 161-167
24. Merlin J.L., Azzi S., Lignon D., Ramacci C., and Zeghari N. MTT assays allow quick and reliable measurement of the response of human tumour cells to photodynamic therapy. Eur J Cancer 28A (1992) 1452-1458
25. Brandis A., Mazor O., Neumark E., Rosenbach-Belkin V., Salomon Y., and Scherz A. Novel water-soluble bacteriochlorophyll derivatives for vascular-targeted photodynamic therapy: synthesis, solubility, phototoxicity and the effect of serum proteins. Photochem Photobiol 81 (2005) 983-993
26. Castano A.P., Mroz P., and Hamblin M. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6 (2006) 535-545
27. Roberts D.J.H., Caimduff F., Driver I., Dixon B., and Brown S.B. Tumour vascular shutdown following photodynamic therapy based on polyhaematoporphyrin or 5-aminolaevulinic acid. Int J Oncol 5 (1994) 763-768
28. Matin S.F., Tinkey P.T., Borne A.T., Stephens Lc, Sherz A., and Swanson D.A. A pilot trial of vascular targeted photodynamic therapy for renal tissue. J Urol 180 (2008) 338-342
29. Star W.M. Light delivery and light dosimetry for photodynamic therapy. Lasers Med Sci 107 (1990) 107-113
30. Furuse K., Fukuoka M., Kato H., Horal T., Kubota K., Kodama N., et al. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early-stage lung cancer. The Japan Lung Cancer Photodynamic Therapy Study Group. J Clin Oncol 11 (1993) 1852-1857
31. Jamieson N.F., Thorpe S., Mosse A., Bown S.G., and Lovat L.G. Photodynamic therapy using MTHPC for early Barrett's-associated cancer. Gut 52 suppl.1 (2003) 170
32. Wong K.E.E., Song L.M., Wang K.K., and Zinsmeister A.R. Mono-l-aspartat chlorine e6 (NPe6) and hematoporphyrin derivate (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model. Cancer 82 (1998) 421-427
33. Bown et al. Photodynamic therapy for cancer of the pancreas. Gut 2002;50:549-57
34. Woodburn K.W., Engelman C.J., and Blumenkranz M.S. Photodynamic therapy for choroidal neovascularization: a review. Retina 22 (2002) 391-405
35. Wojtyk J.T.C., Goyan R., Gudgin-Dickson E., and Pottier R. Exploiting tumour biology to develop novel drug delivery strategies for PDT. Med Laser Appl 21 (2006) 225-238